Plant-based anti-HIV-1 strategies: Vaccine molecules and antiviral approaches

Expert Review of Vaccines

Volumn 9, Issue 8, 2010, Pages 925-936

  Scotti, Nunzia ^a   Buonaguro, Luigi ^b   Tornesello, Maria Lina ^b   Cardi, Teodoro ^a   Buonaguro, Franco Maria ^b  

^a CNR   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

HIV; plant based pharmaceutical; protein accumulation; recombinant protein; transgenic plant; vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MICROBICIDE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; ANTIVIRUS AGENT;

CELLULAR IMMUNITY; CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VACCINE PRODUCTION; BIOSYNTHESIS; BIOTECHNOLOGY; GENETICS; HIV INFECTIONS; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; TRANSGENIC PLANT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; AIDS VACCINES; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BIOTECHNOLOGY; HIV INFECTIONS; HUMANS; PLANTS, GENETICALLY MODIFIED; TECHNOLOGY, PHARMACEUTICAL;

EID: 77955257452     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.79     Document Type: Review

References (92)

1. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N. Engl. J. Med. 356(20), 2073-2081 (2007).
2. Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L. Progress towards development of an HIV vaccine: a report of the AIDS Vaccine 2009 conference. Lancet Infect. Dis. 10(5), 305-316 (2010).
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
4. Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr. Mol. Med. 3(3), 183-193 (2003).
5. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21(3), 346-351 (2009).
6. Gurunathan S, Habib RE, Baglyos L et al. Use of predictive markers of HIV disease progression in vaccine trials. Vaccine 27(14), 1997-2015 (2009).
7. Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R. Molecular farming in plants: host systems and expression technology. Trends Biotechnol. 21, 570-578 (2003).
8. Yusibov V, Rabindran S. Recent progress in the development of plant derived vaccines. Expert Rev. Vaccines 7(8), 1173-1183 (2008).
9. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. 6, 219-226 (2001).
10. Ma JK-C, Drake PMW, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genetics 4, 794-805 (2003).
11. Streatfield SJ. Approaches to achieve high-level heterologous protein production in plants. Plant Biotechnol. J. 5(1), 2-15 (2007).
12. Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. The trans- activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44(6), 941-947 (1986).
13. Fisher AG, Feinberg MB, Josephs SF et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 320(6060), 367-371 (1986).
14. Brigati C, Giacca M, Noonan DM, Albini A. HIV Tat, its targets and the control of viral gene expression. FEMS Microbiol. Lett. 220(1), 57-65 (2003).
15. Ensoli B, Fiorelli V, Ensoli F et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 20, 2245-2261 (2006).
16. Kim TG, Ruprecht R, Langridge WH. Synthesis and assembly of a cholera toxin B subunit SHIV 89.6p Tat fusion protein in transgenic potato. Protein Expr. Purif. 35(2), 313-319 (2004). (Pubitemid 38718093)
17. Karasev AV, Foulke S, Wellens C et al. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach. Vaccine 23, 1875-1880 (2005).
18. Webster DE, Thomas MC, Pickering R et al. Is there a role for plant-made vaccines in the prevention of HIV/AIDS? Immunol. Cell. Biol. 83(3), 239-247 (2005).
19. Ramirez YJP, Tasciotti E, Gutierrez- Ortega A et al. Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice. Clin. Vaccine Immunol. 14(6), 685-692 (2007).
20. Cueno ME, Hibi Y, Karamatsu K et al. Preferential expression and immunogenicity of HIV-1 Tat fusion protein expressed in tomato plant. Transgenic Res. DOI: 10.1007/s11248- 009-9358-9359 (2010) (Epub ahead of print).
21. Das SR, Jameel S. Biology of the HIV Nef protein. Ind. J. Med. Res. 121, 315-332 (2005).
22. Cosma A, Nagaraj R, Buhler S et al. Therapeutic vaccination with MVA- HIV-1 Nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22(1), 21-29 (2003).
23. Marusic C, Vitale A, Pedrazzini E et al. Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study. Transgenic Res. 18(4), 499-512 (2009).
24. Marusic C, Nuttall J, Buriani G et al. Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells. BMC Biotechnol. 7, 12 (2007).
25. Barbante A, Irons S, Hawes C, Frigerio L, Vitale A, Pedrazzini E. Anchorage to the cytosolic face of the endoplasmic reticulum membrane: a new strategy to stabilize a cytosolic recombinant antigen in plants. Plant Biotechnol. J. 6, 560-575 (2008).
26. de Virgilio M, De Marchis F, Bellucci M et al. The human immunodeficiency virus antigen Nef forms protein bodies in leaves of transgenic tobacco when fused to zeolin. J. Exp. Bot. 59, 2815-2829 (2008).
27. Zhou F, Badillo-Corona JA, Karcher D et al. High-level expression of human immunodeficiency virus antigens from the tobacco and tomato plastid genomes. Plant Biotechnol. J. 6(9), 897-913 (2008).
28. Lombardi R, Circelli P, Villani M et al. High-level HIV-1 Nef transient expression in Nicotiana benthamiana using the P19 gene silencing suppressor protein of artichoke mottled crinckle virus. BMC Biotechnol. 9(1), 96 (2009).
29. Kahlau S, Bock R. Plastid transcriptomics and translatomics of tomato fruit development and chloroplast-to- chromoplast differentiation: chromoplast gene expression largely serves the production of a single protein. Plant Cell 20(4), 856-874 (2008).
30. Hennig A, Bonfig K, Roitsch T, Warzecha H. Expression of the recombinant bacterial outer surface protein A in tobacco chloroplasts leads to thylakoid localization and loss of photosynthesis. FEBS J. 274(21), 5749-5758 (2007).
31. Morikawa Y. HIV capsid assembly. Curr. HIV Res. 1, 1-14 (2003).
32. Freed EO. HIV-1 Gag proteins: diverse functions in the virus life cycle. Virology 251, 1-15 (1998).
33. Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59(1), 103-112 (1989).
34. Deml L, Speth C, Dierich MP, Wolf H, Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol. 42(2), 259-277 (2005).
35. Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev. Vaccines 8(10), 1379-1398 (2009).
36. Buonaguro L, Buonaguro FM, Tornesello ML et al. High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 49, 35-47 (2001).
37. Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol. 79(11), 7059-7067 (2005).
38. Buonaguro L, Devito C, Tornesello ML et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25(32), 5968-5977 (2007).
39. Meyers A, Chakauya E, Shephard E et al. Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol. 8, 53 (2008).
40. Scotti N, Alagna F, Ferraiolo E et al. High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta 229(5), 1109-1122 (2009).
41. Maliga P. Engineering the plastid genome of higher plants. Curr. Opin. Plant Biol. 5, 164-172 (2002).
42. Tregoning JS, Nixon P, Kuroda H et al. Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic Acids Res. 31, 1174-1179 (2003).
43. Zhang G, Leung C, Murdin L, Rovinski R, White KA. In planta expression of HIV-1 p24 protein using an RNA plant virus- based expression vector. Mol. Biotechnol. 14, 99-107 (2000).
44. Zhang GG, Rodrigues L, Rovinski R, White KA. Production of HIV-1 p24 protein in transgenic tobacco plants. Mol. Biotechnol. 20, 131-136 (2002).
45. Perez-Filgueira DM, Brayfield BP, Phiri S, Borca MV, Wood C, Morris TJ. Preserved antigenicity of HIV-1 p24 produced and purified in high yields from plants inoculated with a tobacco mosaic virus (TMV) -derived vector. J. Virol. Methods 121, 201-208 (2004).
46. Lindh I, Kalbina I, Thulin S et al. Feeding of mice with Arabidopsis thaliana expressing the HIV-1 subtype C p24 antigen gives rise to systemic immune responses. APMIS 116(11), 985-994 (2008).
47. Lindh I, Wallin A, Kalbina I et al. Production of the p24 capsid protein from HIV-1 subtype C in Arabidopsis thaliana and Daucus carota using an endoplasmic reticulum-directing SEKDEL sequence in protein expression constructs. Protein Expr. Purif. 66(1), 46-51 (2009).
48. Obregon P, Chargelegue D, Drake PMW et al. HIV-1 p24-immunoglobulin fusion molecule: a new strategy for plant-based protein production. Plant Biotechnol. J. 4, 195-207 (2006).
49. McCabe MS, Klaas M, Gonzalez-Rabade N et al. Plastid transformation of high- biomass tobacco variety Maryland Mammoth for production of human immunodeficiency virus type 1 (HIV-1) p24 antigen. Plant Biotechnol. J. 6, 914-929 (2008).
50. Yusibov V, Modelska A, Steplewski K et al. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc. Natl Acad.. Sci. USA 94(11), 5784-5788 (1997).
51. Durrani Z, McInerney TL, McLain L et al. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J. Immunol. Methods 220(1-2), 93-103 (1998).
52. Marusic C, Rizza P, Lattanzi L et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 75(18), 8434-8439 (2001).
53. Kim TG, Gruber A, Langridge WH. HIV-1 gp120 V3 cholera toxin B subunit fusion gene expression in transgenic potato. Protein Expr. Purif. 37(1), 196-202 (2004).
54. Matoba N, Kajiura H, Cherni I et al. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Plant Biotechnol. J. 7(2), 129-145 (2009).
55. Shchelkunov S, Sa lyaev R, Poz dnya kov S et al. Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses. Biotechnol. Lett. 28, 959-967 (2006).
56. Greco R, Michel M, Guetard D et al. Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine. Vaccine 25, 8228-8240 (2007).
57. Guetard D, Greco R, Cer vantes Gonzalez M et al. Immunogenicity and tolerance following HIV-1/HBV plant- based oral vaccine administration. Vaccine 26(35), 4477-4485 (2008).
58. Sexton A, Drake PM, Mahmood N, Harman SJ, Shattock RJ, Ma JKC. Transgenic plant production of cyanovirin-N, an HIV microbicide. FASEB J. 20, 356-358 (2006).
59. Sexton A, Harman S, Shattock RJ, Ma JKC. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J. 23(10), 3590-3600 (2009).
60. O'Keefe BR, Vojdani F, Buffa V et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl Acad. Sci. USA 106(15), 6099-6104 (2009).
61. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68(8), 4821-4828 (1994).
62. Trkola A, Purtscher M, Muster T et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70(2), 1100-1108 (1996).
63. Conley AJ, II KJA, Boots LJ et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp4l human monoclonal antibody. Proc. Natl Acad. Sci. USA 91, 3348-3352 (1994).
64. Zwick MB, Labrijn AF, Wang M et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75(22), 10892-10905 (2001). (Pubitemid 33034579)
65. Sack M, Paetz A, Kunert R et al. Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J. 21(8), 1655-1664 (2007).
66. Floss DM, Sack M, Stadlmann J et al. Biochemical and functional characterization of anti-HIV antibody-ELP fusion proteins from transgenic plants. Plant Biotechnol. J. 6(4), 379-391 (2008).
67. Rademacher T, Sack M, Arcalis E et al. Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc-N-glycans. Plant Biotechnol. J. 6(2), 189-201 (2008).
68. Ramessar K, Rademacher T, Sack M et al. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc. Natl Acad. Sci. USA 105(10), 3727-3732 (2008).
69. Strasser R, Stadlmann J, Schahs M et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6(4), 392-402 (2008).
70. Floss DM, Sack M, Arcalis E et al. Influence of elastin-like peptide fusions on the quantity and quality of a tobacco- derived human immunodeficiency virus-neutralizing antibody. Plant Biotechnol. J. 7(9), 899-913 (2009).
71. Strasser R, Castilho A, Stadlmann J et al. Improved virus neutralization by plant- produced anti-HIV antibodies with a homogeneous (31,4-galactosylated N-glycan profile. J. Biol. Chem. 284(31), 20479-20485 (2009).
72. Jin C, Altmann F, Strasser R et al. A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology 18(3), 235-241 (2008).
73. Bardor M, Faveeuw C, Fitchette AC et al. Immunoreactivity in mammals of two typical plant glyco-epitopes, core a(1,3)- fucose and core xylose. Glycobiology 13(6), 427-434 (2003).
74. Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, Gleba Y. In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc. Natl Acad. Sci. USA 101(18), 6852-6857 (2004).
75. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl Acad. Sci. USA 89(24), 11745-11749 (1992).
76. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl Acad. Sci. USA 93(11), 5335-5340 (1996).
77. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182(1), 302-305 (2000).
78. Arakawa T, Chong DK, Langridge WH. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 16(3), 292-297 (1998).
79. Arakawa T, Yu J, Langridge WH. Food plant-delivered cholera toxin B subunit for vaccination and immunotolerization. Adv. Exp. Med. Biol. 464, 161-178 (1999).
80. Staub JM, Garcia B, Graves J et al. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat. Biotechnol. 18(3), 333-338 (2000).
81. D'Aoust MA, Couture MM, Charland N et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 8(5), 607-619 (2010).
82. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 464(7286), 224-231 (2010).
83. Koff WC. Accelerating HIV vaccine development. Nature 464(7286), 161-162 (2010).
84. Darbinian-Sarkissian N, Darbinyan A, Otte J et al. p27(SJ), a novel protein in St John's Wort, that suppresses expression of HIV-1 genome. Gene Ther. 13(4), 288-295 (2006).
85. Darbinian N, Popov Y, Khalili K, Amini S. Creation of a bi-directional protein transduction system for suppression of HIV-1 expression by p27SJ. Antiviral Res. 79(2), 136-141 (2008).
86. McCormick AA, Reddy S, Reinl SJ et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a Phase I clinical study. Proc. Natl Acad. Sci. USA 105(29), 10131-10136 (2008).
87. Bokesch HR, O'Keefe BR, McKee TC et al. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 42(9), 2578-2584 (2003).
88. Alexandre KB, Gray ES, Lambson BE et al. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, griffithsin, cyanovirin-N and scytovirin. Virology 402(1), 187-196 (2010).
89. UNAIDS: The Joint United Nations Programme on HIV/AIDS www.unaids.org
90. Nonhuman primates HIV/SIV vaccine trials database www.hiv.lanl.gov/ content/vaccine/home.html
91. I AVIReport: AIDS vaccine trials database www.iavireport.org/trials-db
92. Pharma-Planta: resources www.pharma-planta.org/resources.htm